Android app on Google Play

BMO Capital Upgrades Nektar Therapeutics (NKTR) to Outperform

September 22, 2009 9:26 AM EDT Send to a Friend
Get Alerts NKTR Hot Sheet
Price: $12.07 --0%

Rating Summary:
    7 Buy, 1 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 16 | Down: 12 | New: 33
Trade NKTR Now!
Join SI Premium – FREE
BMO Capital upgrades Nektar Therapeutics (Nasdaq: NKTR) from Market Perform to Outperform. Price target $12.

To see more analyst ratings on NKTR Click Here.

Nektar Therapeutics, a biopharmaceutical company, develops various drug products and product candidates using its proprietary drug delivery technologies.



You May Also Be Interested In


Related Categories

Upgrades

Related Entities

BMO Capital

Add Your Comment